Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   221 Trials   11162 News 


«12...130131132133134135136137138139140141142»
  • ||||||||||  Trial completion date, Trial primary completion date:  Myasthenia Gravis and Psyche (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=4300, Recruiting, 
    Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon. Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial primary completion date:  Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) -  Jan 18, 2018   
    P2,  N=40, Recruiting, 
    Trial primary completion date: Sep 2017 --> Sep 2019 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder. (Pubmed Central) -  Jan 5, 2018   
    This is the first case, to our knowledge, reported in association with bladder cancer. The precise diagnosis of MG has important implications on management, as treatment with steroids can transiently worsen myasthenia in nearly 50% of cases.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Trial primary completion date:  Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) -  Jan 5, 2018   
    P3,  N=20, Recruiting, 
    The precise diagnosis of MG has important implications on management, as treatment with steroids can transiently worsen myasthenia in nearly 50% of cases. Trial primary completion date: Oct 2017 --> Jun 2018
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Trial primary completion date:  Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) -  Nov 1, 2017   
    P2,  N=25, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2018
  • ||||||||||  prednisone / Generic mfg., azathioprine / Generic mfg.
    Trial completion, Trial primary completion date:  MYACOR: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis (clinicaltrials.gov) -  Sep 27, 2017   
    P4,  N=118, Completed, 
    N=10000 --> 20000 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017
  • ||||||||||  Biomarker, Enrollment open, Enrollment change, Trial primary completion date:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  Sep 11, 2017   
    P=N/A,  N=440, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017 Terminated --> Recruiting | N=35 --> 440 | Trial primary completion date: May 2017 --> Jun 2022
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Is MuSK myasthenia gravis linked to IgG4-related disease? (Pubmed Central) -  Aug 19, 2017   
    She was started on rituximab with clinical improvement and ability to taper immunomodulatory agents for the first time. Our case raises number of questions regarding a potential link between MuSK MG and IgG4-RD which may shed further light on the pathophysiology and management of these diseases.
  • ||||||||||  Trial completion:  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) -  Jul 11, 2017   
    P2,  N=32, Completed, 
    Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon. Active, not recruiting --> Completed
  • ||||||||||  New trial:  Myasthenia Gravis and Psyche (clinicaltrials.gov) -  Jul 2, 2017   
    P=N/A,  N=4300, Recruiting, 
  • ||||||||||  Trial primary completion date:  MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=42, Recruiting, 
    These data suggest a potential new treatment approach for a population of patients with limited treatment options and support the evaluation of nivolumab and nivolumab plus ipilimumab in phase 3 randomised controlled trials in SCLC. Trial primary completion date: Mar 2017 --> Oct 2018
  • ||||||||||  Biomarker, Enrollment change, Trial termination, Trial primary completion date:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  May 9, 2017   
    P=N/A,  N=35, Terminated, 
    Initiation date: Nov 2015 --> Mar 2016 N=270 --> 35 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> May 2017
  • ||||||||||  Trial primary completion date:  The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) -  Apr 21, 2017   
    P=N/A,  N=80, Active, not recruiting, 
    N=270 --> 35 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> May 2017 Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  bortezomib / Generic mfg.
    Trial primary completion date:  Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) -  Apr 21, 2017   
    P2,  N=18, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Biomarker, Enrollment open:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  Apr 4, 2017   
    P=N/A,  N=270, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Myasterix (CV-MG01) / CuraVac
    Enrollment closed, Enrollment change, Trial primary completion date, IO biomarker:  Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) -  Mar 21, 2017   
    P1/2,  N=24, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017
  • ||||||||||  Enrollment closed:  Tissue Repository for Studies of Myasthenia Gravis (clinicaltrials.gov) -  Mar 7, 2017   
    P=N/A,  N=300, Active, not recruiting, 
    Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment open, Trial primary completion date:  SAA: Serum Auto-Antibodies in Neurological Diseases (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=120, Enrolling by invitation, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Jun 2015 --> Dec 2020